A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

Inclusion Criteria: * Documentation of Disease: * Patients must have pathologic confirmation of one of three diseases: * Diffuse pleural mesothelioma (DPM) * Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach. * PD-L1 CPS ≥1 (using clone 73-10, DAKO) * HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio \<2 and average HER2 copy number \<6.0 signals/cell * Urothelial carcinoma (UC) * Archival tissue is acceptable; diagnosis may be confirmed…